Serum amyloid A in HFpEF and cardiometabolic diseases
Basic Research in Cardiology · 28.11.2025 · 121 (1) · 1-21
DOI: 10.1007/s00395-025-01150-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Basic Research in Cardiology, online erschienen am 28.11.2025. Verfasst von Luo Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité (DHZC), Max Rubner Center for Cardiovascular Metab…. Hauptthemen laut MEDLINE: Serum Amyloid A Protein, Heart Failure, Stroke Volume, Metabolic Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DZHK, Charité - Universitätsmedizin Berlin.
Abstract (Originalsprache)
Heart failure with preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases, and its prevalence is projected to rise further. Among its heterogeneous subtypes, cardiometabolic HFpEF, which is driven by metabolic dysfunction, represents a globally predominant form. Recent advances in preclinical models have highlighted metabolic disturbances and systemic inflammation as key contributors to HFpEF pathogenesis. While much attention has focused on classical inflammatory mediators such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), the full spectrum of upstream inflammatory drivers and the therapeutic strategies targeting inflammation in cardiometabolic HFpEF remain incompletely defined. Among emerging candidates, serum amyloid A (SAA) family proteins, highly inducible acute-phase proteins, have attracted growing attention due to their elevated levels in chronic metabolic diseases. Here, we summarize clinical associations between elevated SAA levels and major cardiometabolic conditions—including obesity, diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), and hypertension—and discuss potential mechanisms based on preclinical studies. We place particular emphasis on the known and potential pathogenetic role of SAA in cardiometabolic HFpEF, where it may contribute to systemic inflammation, endothelial dysfunction, and myocardial fibrosis. Overall, this review aims to advance understanding of SAA in HFpEF and cardiometabolic disease, and to support translational efforts toward improved diagnosis and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité (DHZC), Max Rubner Center for Cardiovascular Metabolic Renal Research (MRC), Charité-Universitätsmedizin Berlin, Berlin,…
- DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany.
- Translational Approaches in Heart Failure and Cardiometabolic Disease, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
- DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany. gabriele.schiattarella@dhzc-charite.de.
- Translational Approaches in Heart Failure and Cardiometabolic Disease, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. gabriele.schiattarella@dhzc-charite.de.
- Friede Springer Cardiovascular Prevention Center at Charité - Universitätsmedizin Berlin, Berlin, Germany. gabriele.schiattarella@dhzc-charite.de.
ORCID-Profile: Gabriele G Schiattarella
Förderung
- DZHK
- Charité - Universitätsmedizin Berlin
Zitieren
APA
Liu, L., Wang, R., Strocchi, S., Eroglu, T., Nambiar, N., Liévano Contreras, S. V., Diezel, S. A., & Schiattarella, G. G. (2025). Serum amyloid A in HFpEF and cardiometabolic diseases. Basic Research in Cardiology, 121(1), 1-21. https://doi.org/10.1007/s00395-025-01150-9
Vancouver
Liu L, Wang R, Strocchi S, Eroglu T, Nambiar N, Liévano Contreras SV, et al. Serum amyloid A in HFpEF and cardiometabolic diseases. Basic Research in Cardiology. 2025;121(1):1-21. doi:10.1007/s00395-025-01150-9
BibTeX
@article{Liu2025,
author = {Liu, Luo and Wang, Rongling and Strocchi, Stefano and Eroglu, Tolga and Nambiar, Natasha and Liévano Contreras, Sarah V and Diezel, Saskia A and Schiattarella, Gabriele G},
title = {Serum amyloid A in HFpEF and cardiometabolic diseases},
journal = {Basic Research in Cardiology},
year = {2025},
volume = {121},
number = {1},
pages = {1--21},
doi = {10.1007/s00395-025-01150-9}
}
EUVIMED